At Astellas, we aim to turn innovative science into value for patients. We foster breakthrough discoveries through the discovery, development and delivery of meaningful scientific advancement by focusing on the best science, empowering the best talent to pursue it and developing it in the location where it has the best chance of succeeding. That is why Astellas has long invested in academic, biotechnology and venture capital collaborations in the greater Boston area, a world-leading hub of emerging and meaningful scientific innovation.
In partnership with top academic research institutes and biotechnology companies, more than 200 Astellas colleagues at sites in Cambridge and Marlborough are combining an in-depth understanding of the underlying biology of diseases with innovative platforms and treatment modalities in four areas of primary focus: antigen-specific immunomodulation, immuno-oncology, mitochondrial function and regenerative medicine.
Click here to learn more about our “Science First” approach to Innovation, and explore below our areas of Primary Focus.
Antigen-specific Immune Modulation
Astellas is developing innovative platforms to potentially create curative therapeutics for autoimmune diseases, infectious diseases and allergies.
Through a range of novel immuno-oncology programs, Astellas is studying using the body’s own immune system to seek, recognize and destroy tumors.
Mitobridge, an Astellas company, is developing novel therapeutics to improve mitochondrial function and potentially impact multiple disease pathologies.
Partnering with Purpose: Astellas Innovation Management
Astellas Innovation Management (AIM) creates mutually beneficial partnerships to help maximize the potential of our partners’ innovations. Combining flexible collaboration structures with our scientific expertise and global operations, we work to deliver novel therapeutics that may improve the lives of patients.